Featured Program
Featured Resources
Featured Advocacy Letters
NCL Sends Letter to Senate HELP Committee on Lowering Healthcare Costs
/in Featured Home - Health/by allisoncAugust 1, 2025: Washington, DC – On July 31, 2025, the Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing on the rising cost of healthcare and the urgent need for patient-focused reform. Lawmakers and expert witnesses discussed challenges with employer-sponsored insurance, the lack of price transparency, and the profit-driven nature of the U.S. healthcare system.
Featured Press Releases
NCL Applauds Subcommittee Passage of Safety is Not For Sale, PART Act
/in Featured Home - Traffic Safety/by allisoncFebruary 12, 2025: Washington, DC – The House Subcommittee on Commerce, Manufacturing, and Trade on Tuesday reported 12 bills to full committee that seek to improve roadway safety, strengthen American automobile manufacturing, and protect vehicle owners from unfair business practices. The National Consumers League (NCL) submitted a letter for the record, urging Congress to enact critical reforms to save lives, reduce injuries, support innovation, and spur economic growth.
Live Nation Litigation Must Continue Despite Possible Interference
/in Featured Home - Fraud Prevention/by Lisa McDonaldFebruary 12, 2025: Washington, DC – Recent turbulence at the Department of Justice (DOJ) Antitrust Division has culminated in the absence of its top leadership, including now-former Assistant Attorney General Gail Slater. NCL is deeply concerned about the potential impact this disruption could have on the Division’s ability to pursue antitrust enforcement consistently, independently, and in the public interest. Leadership instability at such a critical moment raises serious questions about whether major cases – including the ongoing litigation against Live Nation-Ticketmaster, which NCL has long supported – will be carried through to their conclusion.
National Consumers League Commends FDA for Swift Action Against Hims & Hers
/in Featured Home - Food, Nutrition, & Obesity/by Lisa McDonaldFebruary 9, 2026: Washington, DC – You can fool some of the people some of the time and all of the people some of the time. But you can’t fool all of the people all the time. On Friday, February 6, the Food and Drug Administration announced it would stop the telehealth platform Hims & Hers from marketing a compounded version of the first FDA-approved GLP-1 weight-loss pill. On Saturday, Hims & Hers said it was withdrawing the product from the market, and the FDA did not pursue enforcement action.
NCL Issues a Second Alert to Heed Warnings About Unregulated Versions of GLP-1 Weight Loss Drugs
/in Featured Home - Food, Nutrition, & Obesity/by allisoncFebruary 4, 2026: Washington, DC – A year ago, the National Consumers League took the unusual step of flagging warnings from the Food and Drug Administration (FDA) and medical societies stating that compounded versions of GLP-1 (glucagon-like peptide-1 receptor agonists) weight-loss drugs are not FDA approved and may cause serious health problems. The purpose was to inform consumers about the potential harm posed by these drugs before Hims & Hers, a large telehealth company, aired a widely hyped television ad during the 2025 Super Bowl touting only the benefits of compounded GLP-1s.